webinar: amx0035 results - implications for people with als
Published 4 years ago • 1.4K plays • Length 35:55Download video MP4
Download video MP3
Similar videos
-
58:18
amylyx's als drug amx0035 shows promising phase 2/3 clinical trial results
-
57:08
amx0035 research update 19oct20
-
2:04
sabrina paganoni, md, phd: amx0035 and the future of als care
-
3:40
amx0035 in als: long-term survival analysis of the centaur trial
-
1:23:05
mda engage webinar: clinical trials and the als community
-
29:04
sabrina paganoni, md, phd discussion on healey als platform trial and amx0035 help & hope 2021
-
11:30
amx0035 approved
-
2:00:08
webinar 2: bnabs for the prevention of hiv acquisition in newborn and infants
-
1:03:18
community conversation: amx0035 in the fda’s approval process
-
25:49
updates in amyotrophic lateral sclerosis (als)
-
51:40
clinical trials webinar 3: expanded access programs (eap)
-
3:02
sabrina paganoni, md, phd: amx0035 phase 2 performance in als
-
29:46
"expediting access to a promising new als drug…"
-
53:20
healey als platform trial mechanism of action & science: verdiperstat
-
55:24
challenges in drug development for als
-
2:04
sabrina paganoni, md, phd: takeaways from the centaur trial of amx0035
-
0:58
#approveamx0035
-
2:54
sabrina paganoni, md, phd: collaboration in the centaur trial of amx0035 in als
-
1:04:56
webinar series: the evolving landscape of therapeutic targets in als clinical trials 2022